Antiangiogenesis: Biology and utility in the treatment of gliomas

Expert Review of Neurotherapeutics

Volumn 8, Issue 10, 2008, Pages 1419-1423

  Chamberlain, Marc C ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; DEXAMETHASONE; IRINOTECAN; STEROID; TEMOZOLOMIDE; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BLOOD VESSEL PERMEABILITY; CANCER SURVIVAL; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIGESTIVE SYSTEM PERFORATION; EDITORIAL; ENDOTHELIUM CELL; EPISTAXIS; GLIOBLASTOMA; GLIOMA; HUMAN; HYPERTENSION; MONOTHERAPY; ORAL BLEEDING; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEINURIA; RECURRENT CANCER; RISK FACTOR; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR BLEEDING; TUMOR VASCULARIZATION; UBIQUITINATION; UNSPECIFIED SIDE EFFECT; VAGINA BLEEDING; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; GLIOMA; HUMANS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 54249083501     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.10.1419     Document Type: Editorial

References (55)

1. Lakka SS, Rao JS. Anti-angiogenic therapy in brain tumors. Expert Rev. Neurother. 8(10), 1457-1473 (2008).
2. Bergers G, Benjamin L. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3(6), 401-410 (2003).
3. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86(3), 353-364 (1996).
4. Kerbel RS. Tumor angiogenesis. N. Engl. J. Med. 358(19), 2039-2044 (2008).
5. Semenza GL. A new weapon for attaching tumor blood vessels. N. Engl. J. Med. 358(19), 2066-2067 (2008).
6. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319, 195-198 (2008).
7. Nolan DJ, Ciarrocchi A, Mellick AS et al. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev. 21, 1546-1558 (2007).
8. Peters BA, Diaz LA, Polyak K et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat. Med. 11, 261-262 (2005).
9. Rajantie I, Ilmonen M, Alminaite A et al. Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 104(7), 2084-2086 (2004).
10. + cells contribute to the endothelium of tumor vessels in mouse brain. Clin. Neurosurg. 52, 384-388 (2005).
11. Leenders WP, Küsters B, Verrijp K et al. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin. Cancer Res. 10, 6222-6230 (2004).
12. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9(6), 669-676 (2003).
13. Kowanerz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin. Cancer Res. 12(17), 5018-5022 (2006).
14. Fischer I, Gagner JP, Law M et al. Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol. 15(4), 297-310 (2005).
15. Kargiotis O, Rao JS, Kyritsis AP. Mechanisms of angiogenesis in gliomas. J. Neurooncol. 78(3), 281-293 (2006).
16. Lamszus K, Heese O, Westphal M. Angiogenesis-related growth factors in brain tumors. Cancer Treat. Res. 117, 169-190 (2004).
17. Plate KH, Risau W. Angiogenesis in malignant gliomas. Glia 15(3), 339-347 (1995).
18. Jain RK. Normaliziing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7(9), 987-989 (2001).
19. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706), 58-62 (2005).
20. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro-oncology 7(2), 134-153 (2005).
21. Kaur B, Tan C, Brat DJ et al. Genetic and hypoxic regulation of angiogenesis in gliomas. J. Neurooncol. 70(2), 229-243 (2004).
22. Tong RT, Boucher Y, Kozin SV et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64(11), 3731-3736 (2004).
23. Weis SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature 437, 497-504 (2005).
24. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 69(Suppl. 3), 11-16 (2005).
25. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from Phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3(1), 24-40 (2006).
26. Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312(5777), 1171-1175 (2006).
27. Chi A, Norden AD, Wen PY. Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev. Anticancer Ther. 7(11), 1537-1560 (2007).
28. Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J. Clin. Oncol. 21(8), 1624-1636 (2003).
29. Lamszus K, Kunkel P, Westphal M. Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir. 88(Suppl.), 169-177 (2003).
30. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat. Rev. Cancer 3(7), 489-501 (2003).
31. Salhia B, Tran NL, Symons M, Winkles JA, Jutka JT, Berens ME. Molecular pathways triggering glioma cell invasion. Expert Rev. Mol. Diagn. 6(4), 613-626 (2006).
32. Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J. Clin. Oncol. 23(10), 2411-2422 (2005).
33. Abounader R, Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro-oncology 7(4), 436-451 (2005).
34. Kunkel P, Ulbricht U, Bohlen P et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res. 61(18), 6624-6628 (2001).
35. Plate KH, Breier G, Millaauer B et al. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res. 53(23), 5822-5827 (1993).
36. Reardon DA, Wen PY, Desjardins A, Batchelor TT, Vredenburgh JJ. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin. Biol. Ther. 8(4), 541-553 (2008).
37. Samoto K, Ikezaki K, Ono M et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res. 55(5), 1189-1193 (1995).
38. Stefanik DF, Fellows WK, Rizkalla LR et al. Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J. Neurooncol. 55, 91-100 (2001).
39. Stefanik DF, Rizkalla LR, Soi A et al. Acidic and basic fibroblast growth factors are present in glioblastoma multiforme. Cancer Res. 51(20), 5760-5765 (1991).
40. Winkler F, Kozin SV, Tong R et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation angiopoietin-1 and matrix metalloproteinases. Cancer Cell 6, 553-563 (2004).
41. Zagzag D, Zhong H, Scalzitti JM et al. Expression of hypoxia-inducible factor 1α in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88(11), 2606-2618 (2000).
42. Zheng PP, Hop WC, Luider TM et al. Increased levels of circulating endothelial progenitor cells and circulating endothelial nitric oxide synthase in patients with gliomas. Ann. Neurol. 62, 40-48 (2007).
43. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66(8), 1258-1260 (2006).
44. Vredenburgh JJ, Desjardins A, Herndon JE et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res. 13, 1253-1259 (2007).
45. Vredenburgh JJ, Desjardins A, Herndon JE et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25(30), 4722-4729 (2007).
46. 18F] fluorothymidine positron emission tomography: a pilot study. J. Clin. Oncol. 25(30), 4714-4721 (2007).
47. Norden AD, Young GS, Setayesh K et al. Bevacizumab for recurrent malignant glioma: efficacy, toxicity and patterns of recurrence. Neurology 70, 779-787 (2008).
48. Cloughsey TF, Prados MD, Mikkelsen T et al. A Phase II randomized non-comparative trial of bevacizumab alone or in combination with irinotecan on 6-month progression free survival in recurrent treatment refractory glioblastoma. J. Clin. Oncol. 26(Suppl. 15), 91 (2008).
49. Batchelor TT, Sorensen AG, diTomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95 (2007).
50. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 358(11), 1129-1136 (2008).
51. Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors: a review. Eur. J. Cancer 42, 3127-3139 (2006).
52. Brandes AA, Scelzi E, Salmistraro G et al. Incidence of risk of thromboembolism during treatment of high-grade gliomas: a prospective study. Eur. J. Cancer 33, 1592-1596 (1997).
53. Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 89, 640-646 (2000).
54. Semrad TJ, O'Donnell R, Wun T et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J. Neurosurg. l06(4), 601-608 (2007).
55. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro Oncol. 7(3), 369 (2005)(Abstract).